BioNTech SE (BNTX) Reports Q3 EPS of EUR12.35

BioNTech SE (NASDAQ: BNTX) reported Q3 EPS of EUR12.35, versus (EUR0.88) reported last year. Revenue for the quarter came in at EUR6.09 billion, versus EUR67.5 million reported last year.

Guidance:

Estimated BioNTech COMIRNATY/COVID-19 vaccine revenues for the full 2021 financial year based on up to 2.5 billion doses: ~€16 billion to €17 billion2

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance